Microbiome sequencing is driven by growing interest in and research of the human microbiome. Scientists require microbiome sequencing services to understand its function in health and sickness. These services examine microbial collectives.
The microbiome sequencing services industry was made possible by fast sequencing technology. Next-generation sequencing (NGS) technologies and other high-throughput methods are thorough and don't cost much for a deeper look at the microbiome.
There is a lot of demand for microbiome analysis services because of diseases like gastric, immune, and metabolic problems that are linked to microbiomes. Scientists and doctors are looking into the microbe changes that cause these diseases in order to make more effective medicines.
The microbiome sequencing services industry is driven by personalized treatment and learning more about how the microbiota affects health. To make meds that work with each person's microbiome makeup, sequencing services are needed.
Researchers from universities, drug companies, and genome service providers work together to make microbiome study more innovative. Partnerships make it easier to set up data tools, genome services, and ways to use study results, which is good for business.
For microbiome sequencing services to work, bioinformatics and data analysis are necessary. As the amount of genetic data increases, scientists and doctors need better ways to look at large, difficult microbiome collections and learn useful things.
Government grants and microbiome study efforts make microbiome sequencing programs better. Research funding, attempts to raise money, and help from regulators all encourage microbial research and products.
Microbiome sequencing services are driven by what people know and are interested in about their microbiome health. People want direct-to-consumer microbiome sequencing services because they want to know their microbes in order to get personalized advice on diet and health.
Microbiome sequencing is being used in environmental and farming studies, which is making the industry more diverse. Researchers in the field of agriculture study the microbiome of dirt and plants, which expands the market. Environmental studies look at microbe groups in different environments.
The market is affected by the rules and ethics of microbial study. Ethical and legal standards must be followed for microbiome sequencing data to be used in an ethical way, which builds trust among stakeholders.
The need for microbiome analysis is growing because of drug tolerance and cases of infectious diseases. Understanding how bacteria communities change in public health situations helps people come up with solutions that work for the market.
Report Attribute/Metric | Details |
---|---|
Growth Rate | 18% (2023-2032) |
Microbiome Sequencing Services Market Size was valued at USD 1.5 Billion in 2022. The microbiome sequencing services market industry is projected to grow from USD 1.77 Billion in 2023 to USD 6.70 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18% during the forecast period (2023 - 2032). The increased demand for next-generation sequencing, the expansion of microbeam sequencing services, and falling sequencing costs are the key market drivers fostering the growth of the market. The market is being driven by the rising sales of pharmaceutical products and the advantages of microbiome sequencing for cancer treatment.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
At an international conference in October 2024, Second Genome used data from their in-house sequencing methods to deliver studies showing the therapeutic potential of microbiome modification in malignancy.
In March 2024, BIOHM Health Inc., a company focused on microbiome-based wellness solutions, announced a collaborative effort with Virginia Tech. This partnership aimed to leverage artificial intelligence (AI) to develop and commercialize products based on the analysis of bacterial and fungal microbiomes.
In April 2024, Microbiome Insights Inc., a prominent player in microbiome sequencing and analysis, unveiled its new long-read sequencing services for both 16S rRNA gene and metagenomic analysis [[invalid URL removed]]. This launch aimed to equip researchers with a more powerful tool for understanding the complexities of the microbiome.
Market CAGR for microbiome sequencing services is being driven by the rising price of the advanced infrastructure of sequencing. Next-generation sequencing (NGS) systems, bioinformatics tools, and data storage and analysis capabilities are just a few examples of the sophisticated and pricy technology needed for the field of microbiome sequencing. Many academic and research institutions, pharmaceutical and biotechnology firms, and other end users may find the expense of setting up and maintaining such infrastructure exorbitant. Microbiome sequencing outsourcing enables professionals to access cutting-edge technology and know-how without making substantial upfront investments. These service providers frequently feature cutting-edge facilities and knowledgeable staff adept at microbiome sequencing utilizing the most recent tools and techniques. Professionals can utilize the skills of these specialized facilities through outsourcing without having to worry about capital costs, operational costs, and maintenance costs related to in-house infrastructure.
The market for microbiome sequencing services is expected to grow due to significant investments in microbiome research. Demand for next-generation sequencing services and genetic research has increased, which is anticipated to benefit the industry. The range of applications for microbiome sequencing is also expanding. The next-generation sequencing technologies show a fundamental shift in the sequencing industry. This technological know-how has been applied to biological study, leading to a surprising and profound grasp of the molecular biology of the cell. Budgets for research and development initiatives have steadily increased over the past ten years. Every pharmaceutical company wants its products to be successful on the market.
The substantial virus research conducted by the government in collaboration with business stakeholders also contributed to the pandemic's high demand for microbiome sequencing. In the UK, a genome sequencing collaboration was established in March 2020 to enable quick, thorough, and extensive sequencing examination of samples from individuals whose COVID-19 testing was positive. The network will sequence every patient sample that tested positive for the virus. Oxford Nanopore is happy to support the teams in the UK working on this effort. Thus, driving the microbiome sequencing services market revenue.
The microbiome sequencing services market segmentation, based on technology, includes sequencing by litigation (SBL), sequencing by synthesis (SBS), short gun sequencing, targeted gene sequencing, RNA sequencing, and others. The sequencing by synthesis (SBS)segment dominated the market, accounting for 42.1% of market revenue (0.6 Billion). SBS makes analyzing the microbiome efficient and affordable by concurrently enabling high-throughput sequencing of millions of DNA fragments. Shotgun sequencing applications are used in market segments that are the fastest growing segment. The industry is experiencing increased demand due to its prevalence and the need for efficient treatment methods. The shotgun accelerates the market's growth rate because it is more practical and affordable than any alternative option.
Figure 1: Microbiome Sequencing Services Market, by Technology, 2022 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The microbiome sequencing services market segmentation, based on application, includes gastrointestinal diseases, infectious diseases, cns diseases, oncology, and others. The oncology sector dominates the market for microbiome sequencing services. Because of the increasing number of cancer cases worldwide and the growth of cancer genomic research, the market for microbiome sequencing services is predicted to increase.
March 2022: Microbiotica has raised USD 67 million for its study on microbiome-based immuno-oncology, which will begin later this year. Microbiotica's two lead oral Live Bacterial Therapeutics (LBTs), MB097 and MB310, will be advanced to Phase 1b clinical trials with the funds. MB097 is a fully characterized LBT comprising a consortium of bacteria that form the foundation of Microbiotica's clinical microbiome signature that predicts patient response to Immune Checkpoint Inhibitor medication.
A significant share belonged to the gastrointestinal area. Various gut-related disorders can result from changes in the microbiome, which is crucial for maintaining the health of the digestive system. Researchers have uncovered important microbial species and their roles in the emergence and progression of gut-related disorders thanks to using microbiome sequencing to analyze the gut microbiome.
By region, the report gives market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American microbiome sequencing services market will dominate due to the rise in the adoption of highly advanced techniques and systems in the microbiome sequencing services and technical improvements made in genomic research investigations. The strong market growth in the region is mostly due to the high awareness among medical professionals about the existence of cutting-edge microbiome sequencing services in the market.
Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.
Figure 2: MICROBIOME SEQUENCING SERVICES MARKET SHARE BY REGION 2022 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe’s microbiome sequencing services market accounts for the second-largest market share. Significant players' presence and increased public awareness of NGS are important drivers of accelerating expansion. The increased use of micro-biomes in genomes, proteomics, and metabolomics is responsible for this region's expansion. Further, the German microbiome sequencing services market held the largest market share, and the UK microbiome sequencing services market was the rapidly growing market in the European region.
The Asia-Pacific Microbiome Sequencing Services Market is expected to grow at a rapid rate from 2023 to 2032. Due to several causes, including increased research funding, increased interest in personalized treatment, and expanding government initiatives to construct cutting-edge healthcare infrastructure, the region's demand for microbiome sequencing services is on the rise. The continual advancement of sequencing technologies and the introduction of novel methods for disease diagnosis are credited with this region's expansion. Moreover, China’s microbiome sequencing services market held the largest market share, and the Indian microbiome sequencing services market was the rapidly growing market in the Asia-Pacific region.
Microbiome Sequencing Services Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the microbiome sequencing services market, grow even more. To increase their worldwide footprint, market participants are also engaging in various strategic actions. Important market developments include introducing new products, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the microbiome sequencing services industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the microbiome sequencing services industry to benefit clients and increase the market sector. In recent years, the microbiome sequencing services industry has offered some of the most significant medical advantages. Major players in the microbiome sequencing services market, including Rancho Biosciences, Metabiomics Corp., EPIBIOME, Baseclear B.V, Microbiome Therapeutics, LLC., and others, are attempting to increase market demand by investing in research and development operations.
Microba Life Sciences Ltd is a commercial-stage firm that uses cutting-edge technology to measure the human gut microbiota and provides gut microbiome testing services to consumers, doctors, and researchers worldwide. Testing Services and Research and Development are two of the company's segments. In February 2023, Microba created a new human gut microbiome testing service to provide comprehensive gastrointestinal testing options. The new human gut microbiome testing product range, launched in Australia, delivers diagnostic gastrointestinal health testing and metagenomic-driven gut microbiome analysis to provide healthcare practitioners with comprehensive gastrointestinal testing solutions.
OraSure Technologies develops, manufactures, and distributes oral fluid diagnostic and collecting systems. Diagnostics and molecular solutions are its reportable segments. The diagnostics branch creates rapid oral diagnostic tests and tools for collecting samples for infectious diseases, including HIV and HCV. In March 2022, OraSure Technologies, Inc. introduced a new service to deliver metatranscriptomic sequencing and analysis of gut microbiome samples through its Diversigen subsidiary. The metatranscriptomic services will build a gene expression profile of a microbial community to inform clients about the interactions between a human and their microbiome and provide a comprehensive picture of a sample's microbial functions and expression levels.
Key Companies in the microbiome sequencing services market include
Microbiome Sequencing Services Industry Developments
January 2022:Eagle Genomics and Quadram Institute have formed a new strategic alliance to speed up microbiome analysis using an AI-augmented knowledge discovery platform and genetic sequencing technology. The collaboration with the Quadram Institute will involve the sharing of datasets, tools, and innovation pipelines to aid in the understanding of complex microbiome data through Eagle Genomics' e[datascientist] platform, building on the agreement with the Earlham Institute, a Norwich-based leader in data-intensive bioscience research.
June 2021:Illumina and Microba Life Sciences have formed a collaboration to better study the role of the human gut microbiome in human health and illness. The collaboration will combine Illumina's ground-breaking NGS techniques with Microba's high-quality proprietary gut microbiome analysis platform to generate the precise metagenomic data researchers need to fuel new discoveries.
Sequencing by Litigation (SBL)
Sequencing by Synthesis (SBS)
Short Gun Sequencing
Targeted Gene Sequencing
RNA Sequencing
Others
Gastrointestinal Diseases
Infectious Diseases
CNS Diseases
Oncology
Others
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)